Page 19 - SLIDES

NABUCCO2 Conclusions

• Ipi 3 + Nivo 1 is more efficacious than Ipi 1 + Nivo 3 as

preoperative Immune checkpoint therapy

• But…..small sample size

• Ipi 1 + Nivo 3 more effective in other cancers, more

tolerability in melanoma

• Dosing trials are necessary

• PD-L1 subgroup analyses not completed yet